Zymeworks Inc

162 articles with Zymeworks Inc

• Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

  7/28/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease.

• Zymeworks to Present at Ladenburg Thalmann Healthcare Conference

  7/8/2021

  Zymeworks Inc. today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 4:00 p.m. ET.

• Zymeworks to Present at Jefferies Virtual Healthcare Conference

  5/26/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company’s presentation will be on Thursday, June 3, 2021 at 10:00 a.m. ET.

• Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting - May 06, 2021

  5/6/2021

  Zymeworks Inc., a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021.

• Zymeworks Reports 2021 First Quarter Financial Results

  5/5/2021

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the first quarter ended March 31, 2021.

• Zymeworks Announces Succession Plan for Chief Medical Officer

  4/19/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D., will be transitioning out of her role as Zymeworks’ Chief Medical Officer (CMO) and assuming an executive advisory role until November 15th, 2021.

• Zymeworks to Present at Bloom Burton Healthcare Conference

  4/13/2021

  Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conference taking place April 20-21, 2021.

• Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

  4/10/2021

  Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce complement dependent cytotoxicity

• Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

  3/10/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 taking place virtually from April 10 – 15, 2021.

• Zymeworks Reports 2020 Year-End Financial Results

  2/24/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.

• Zymeworks to Participate in Upcoming Investor Conferences and Events

  2/10/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences. Guggenheim Healthcare Talks Oncology Days, February 11-12, 2021. Zymeworks will be participating in the event; there is no public presentation. SVB Leerink’s 10 th Annual Global Health

• Zymeworks Expands Commercial Team and Creates New R&D Role

  2/9/2021

  James Priour promoted to Chief Commercial Officer, added to Zymeworks’ Executive Committee John Babcook recognized as Distinguished Fellow

• Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

  1/27/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate (ADC).

• Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

  1/15/2021

  Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021

• Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities

  1/11/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.

• Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

  12/10/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.

• 

  FDA Works to Get New Drugs to Patients Faster with Multiple Approvals This Week

  12/2/2020

  The FDA uses special designations to get new, breakthrough treatments to patients in the greatest need.

• Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene

  12/1/2020

  Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC)

• Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer

  11/30/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab in patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).

• Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

  11/19/2020

  Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.